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Platinum-based chemotherapy persists to be the only effective therapeutic option against a wide variety 51 
of tumours. Nevertheless, the acquisition of platinum resistance is utterly common, ultimately cornering 52 
conventional platinum drugs to only palliative in many patients. Thus, encountering alternatives that are 53 
both effective and non-cross-resistant is urgent. In this work, we report the synthesis, reduction studies, 54 
and luminescent properties of a series of cyclometallated (C,N,N’)PtIV compounds derived from amine–55 
imine ligands, and their remarkable efficacy at the high nanomolar range and complete lack of cross-56 
resistance, as an intrinsic property of the platinacycle, against multiplatinum-resistant colorectal cancer 57 
(CRC) and castration-resistant prostate cancer (CRPC) metastatic cell lines generated for this work. We 58 
have also determined that the compounds are effective and selective for a broader cancer panel, including 59 
breast and lung cancer. Additionally, selected compounds have been further evaluated, finding a shift in 60 
their antiproliferative mechanism towards more cytotoxic and less cytostatic than cisplatin against cancer 61 
cells, being also able to oxidize cysteine residues and inhibit topoisomerase II, thereby holding great 62 
promise as future improved alternatives to conventional platinum drugs. 63 
  64 
Platinum-based chemotherapy is often the only effective treatment Against a broad spectrum of 65 
tumors, even if their success Is limited by side-effects and resistance. Octahedral ptiv compounds Have 66 
been shown to be a very promising kind of prodrugs Since they are kinetically inert compared to ptii 67 
analogues And the two extra coordination positions allow the Tuning of their properties.[1–4] in 68 
particular, multiple action ptiv Prodrugs derived from cisplatin have attracted much attention In recent 69 
years.[5–7] 70 
On the other hand, cyclometallated ptii compounds containing Bidentate (c,n) or tridentate (c,n,n’) 71 
ligands display interesting Properties.[8–10] the presence of a s(pt@c) bond increases The stability of 72 
these compounds, thus allowing them to Reach the cell unaltered. In addition, covalent coordination to 73 
Dna is favoured since the strong pt@c bond increases the lability Of the ligand in a trans position. 74 
Moreover, the presence Of aromatic planar groups might favour intercalative binding To dna through 75 
noncovalent p–p stacking interactions. Furthermore, Several cyclometallated ptii anticancer agents exhibit 76 
Luminescence properties which make them potential luminescent Probes for dna in living cells and also 77 
allows easy tracing Of their cellular uptake and distribution by fluorescence microscopy.[11, 12] 78 
surprisingly, little attention has been devoted to PtIV compounds containing a metallacycle in spite of 79 
their promising properties.[13]  80 
Within the last few years, we have attempted to optimize the ligand design of cyclometallated PtII 81 
and PtIV compounds to maximize their efficacy and selectivity against cancer cells. 82 
Indeed, the present work represents a definitive milestone for the optimization of the general 83 
formulae [PtX(C,N,N’)] and [PtXYZ(C,N,N’)], respectively, in which (C,N,N’) is a terdentate ligand and 84 
X, Y, Z are different ligands such as halido or Cdonor ligands.[14, 15, 16] An additional interesting feature 85 
of these (C,N,N’)-cycloplatinated compounds relies on their luminescence properties since we have 86 
unveiled that the intensity and the energy of the emission can be easily modulated by altering the nature 87 
of the ligands, the size of the (N,N’)-chelate ring and the substituents in the aryl ring.[17, 18] Indeed, this 88 
property of the reported compounds can also be of remarkable interest for in vivo cell imaging and flow 89 
cytometry applications. 90 
The syntheses of the (C,N,N’) cyclometallated Pt compounds studied in this work are summarised 91 
in Scheme 1. These compounds differ in the oxidation state of Pt (II or IV), the length of the hydrocarbyl 92 
chain connecting both nitrogen donor atoms (ethylene or propylene), and the halido ligands (Cl or Br). 93 
The new compounds 2b’, 3a’ and 3b’ were characterised by elemental analyses, mass spectra, and 94 
1H and 19F NMR spectra and the molecular structures of these compounds and the previously reported 95 
compound 2a’ were determined by XRD analysis of suitable crystals (see Figure 1, S1–S7, Supporting 96 
Information). In compounds 2a’ and 2b’ the PtII central atom adopts a square-planar coordination 97 
completed with a tridentate (C,N,N’) ligand and an halido (Cl for 2a or Br for 2a’) ligand trans to the 98 
imine. Both the platinacycle and the chelate rings are nearly coplanar with the coordination plane leading 99 
to more rigid structures than those previously reported for 2a[17] and 2b[18] containing a propylene chain. 100 
For compounds 3a’ and 3b’, the PtIV central atom displays an octahedral coordination with a meridional 101 
tridentate (C,N,N’) ligand and three chlorido (3a’) or bromido (3b’) ligands. The axial ligands form a Cl-102 
Pt-Cl angle of 175.86(8)8 (3a’) or a Br-Pt-Br of 173.85(8)8 (3b’). 103 
Absorption and emission spectra for all compounds were recorded in 5V10@5m dichloromethane 104 
solutions at 298 K. The results are summarized in Table 1. 105 
PtII cyclometallated compounds show several absorption bands in the UV/Visible range (Figure 106 
S8, Supporting Information). The lowest energy bands in the 357–386 nm range can be attributed to 107 
Pt(5d)!p* metal-to-ligand charge transfer (MLCT) mixed with intraligand transitions. An additional high 108 
energy absorption band, observed in the range 275–301 nm with higher e values, can be attributed to p!p* 109 
intraligand transitions, as it matches the absorption recorded for the free ligand (Figure S9, Supporting 110 
Information).[18–20] PtIV compounds only show absorption bands in the high energy range, except for 111 
compound 3b’ which also displays lower energy absorption bands. 112 
When excited at their high energy absorption band, all compounds display a broad emission in the 113 
344–351 nm range assigned as intraligand (1IL) transitions, perturbed by the presence of Pt in the case of 114 
the metal complexes (Figure S10, Supporting Information). Trends observed for PtII compounds, indicate 115 
that higher luminescent quantum yields are recorded for the more rigid compounds, containing a two 116 
carbon hydrocarbyl moiety (2a’>2a and 2b’>2b) and for chlorido derivatives (2a>2b and 2a’>2b’). 117 
Although no clear trends are observed for PtIV compounds, the higher quantum yield is obtained for 118 
compound 3a’ containing chlorido ligands and the more rigid ethylene fragment. PtII complexes and 119 
compound 3b’ also display a vibronically structured emission band in the 576–630 nm range when excited 120 
at their lower energy absorption band (Figure 2). It can be attributed to phosphorescence 3IL emission due 121 
to the observation of a large Stokes’ shift and the quenching of the emission in the presence of oxygen 122 
(Figure S11, Supporting Information).[17, 18] 123 
The stability of the PtIV compound 3a in the aqueous biological medium was evaluated by 1H 124 
NMR spectroscopy in D2O and two drops of [D6]DMSO. The obtained spectra (Figure S12, Supporting 125 
Information) suggests the formation of a mixture of solvato complexes, which is in line with recent 126 
observations of aquation of equatorial ligands of PtIV compounds.[21]  127 
First, we assessed the effect of the PtII and PtIV compounds on the proliferation of a cancer panel 128 
including SW620 (lymph node metastasis of colorectal cancer), PC-3 (bone metastasis of prostate cancer), 129 
A549 (lung adenocarcinoma), and MCF-7 (breast adenocarcinoma). Our results, summarized in Table 2, 130 
indicate that the IC50 of all the compounds except 2a’ and 2b’ were significantly lower than both cisplatin 131 
and oxaliplatin for the breast cancer cell line MCF-7. Also, some of the PtIV compounds displayed IC50 132 
values in the high nanomolar range for SW620 and PC-3. Compound 3a’ was the most effective against 133 
SW620 (0.41 mm), whereas 3a exhibited the highest efficacy against PC-3 (0.9 mm), A549 (1.4 mm) and 134 
MCF-7 (3.3 mm). 135 
We next aimed to evaluate whether these compounds could also be effective against metastatic 136 
tumours that have acquired multiplatinum resistance (MPR), for prostate PC-3-MPR and colorectal 137 
SW620-MPR, along with their age-matched controls, PC-3O or SW620-O (Tables 3 and 4 and see the 138 
Supporting Information). Strikingly, we obseved that 3a–b’ exhibited similar antiproliferative effects in 139 
controls and resistant cells of both metastatic resistant cell models, with resistance indexes (RIresist) close 140 
to 1, denoting a complete absence of cross-resistance. Indeed, other examples of low cross-resistance have 141 
been reported in the literature.[5, 22, 7] However, in such cases, the low cross-resistance is related to the 142 
axial ligands, bioactive agents per se (i.e. HDAC, COX, or PDK inhibitors). On the contrary, in our case 143 
the absence of cross-resistance must arise from the platinacycle itself, since the axial ligands are halogen 144 
groups. In support of this notion, a similar cross-resistance was observed for the PtII structure 2a. 145 
Encouragingly, we also found that 2a, 3a, and 3a’ displayed excellent selectivity profiles for cancer cells 146 
at low doses (1–10 mm), when assessing their antiproliferative effect on all the cancer cell lines tested 147 
compared to normal human foreskin fibroblast cells (BJ) (Figures S13–S14, Supporting Information). 148 
In light of these results, we also investigated if the ability to overcome resistance of the reported 149 
compounds involved an alteration of their cytotoxic and cytostatic activities inside the cell compared to 150 
cisplatin. For that, we studied the effect of 3a’ on the cell cycle phase distribution (Figure 3) and apoptosis 151 
(Figure 4) of SW620-O and SW620-MPR cells. 152 
We found that, compared to cisplatin, 3a’ had only a slight effect on the cell cycle phase 153 
distribution of SW620-O cells (Figure 3A). Moreover, whereas cisplatin appeared to induce a significant 154 
G2/M arrest, consistent with previous observations,[23] 3a’ only occasioned a minor reorganization 155 
between the S and G2/M subpopulations, with no effect on the percentage of cells at G0/G1. Indeed, while 156 
cisplatin caused a 40% reduction in the G0/G1 subpopulation in SW620-O, it only caused a G0/G1 drop 157 
of around 15% in SW620-MPR cells (Figure 3B), with a subsequent G2/M arrest. Interestingly, 3a’ had 158 
no significant effect on the cell cycle of SW620-MPR cells. On the contrary, 3a’ exhibited a much greater 159 
effect on the induction of cell death (PI+ cells) than cisplatin in both SW620-O and SW620-MPR (Figure 160 
4). Preapoptotic cells (PI@/Annexin V+ cells) were only observed in SW620-O at 72 h, and both 161 
compounds had a significantly enhanced effect on SW620-O than in SW620-MPR cells, potentially 162 
denoting that the generated resistant cell lines enhanced their potential to evade apoptosis. In this regard, 163 
apoptosis levels did not correlate with ROS accumulation in the cells treated with either cisplatin or 3a’ 164 
(see Figure S15, Supporting Information).  165 
Previous evidence gathered by our group on different related sets of cyclometallated PtII and PtIV 166 
complexes extensively revealed that cellular accumulation for all platinum cyclometallated compounds 167 
was significantly higher than for cisplatin.[24, 25] However, no correlation was observed between the 168 
cytotoxicity in cancer cells and Pt accumulation within the series of compounds, as previously reported 169 
for other metal complexes.[26, 27] Therefore, more information than just intracellular drug concentration, 170 
such as reduction potential or differential DNA binding affinity is necessary to explain the displayed 171 
enhanced cytotoxicity. 172 
In consequence, the ability of cyclometallated PtII (2a,b, 2a’,b’) and PtIV (3a,b, 3a’,b’) 173 
compounds to modify the mobility of the supercoiled closed (sc) and the open circular (oc) forms of 174 
pBluescript SK+ plasmid DNA was studied in an agarose gel by electrophoresis (Figure 5). For the PtII 175 
complexes significant changes in the mobility of plasmid DNA were observed at 10 mm and even at 5 176 
mm concentration for compounds 2a’ and 2b’. With regard to PtIV compounds only 3b’ showed an 177 
interaction with plasmid DNA at concentrations as high as 100 mm, whereas compounds 3a, 3b and, 3a’ 178 
were not efficient at all in removing the supercoils from DNA.  179 
Since it is generally accepted that PtIV compounds are rapidly reduced under physiological 180 
conditions by cellular reducing agents, the reactions of 3a with ascorbic acid, glutathione, and cysteine 181 
were also monitored by 1H NMR spectroscopy under analogous conditions (Figures S16–S18, Supporting 182 
Information). The reaction with cysteine (Figure S18) was the most conclusive since it produced from the 183 
early stages a compound that is stable in solution for up to one week and that can be assigned to PtII 184 
compound 2a–cys (see Scheme S1, Supporting Information). This result is supported by recent studies 185 
suggesting that cysteine has the highest reactivity toward reduction of PtIV anticancer prodrugs under 186 
physiological conditions and its reactivity is highly sensitive to pH.[28, 29] Additionally, this result is also 187 
in agreement with the kinetics studies previously carried out for 3a and analogous PtIVCl3 compounds[30] 188 
which revealed that the reaction of these cyclometallated PtIV compounds with thiols consists of two 189 
consecutive reaction steps: a PtIV to PtII reduction (step 1 in Scheme S1, Supporting Information) 190 
followed by substitution of the remaining chlorido ligand by cysteine (step 2). 191 
In light of this, we hypothesized if the studied Pt compounds could be inhibitors of cysteine 192 
metalloprotease Cathepsin B, as recently reported for other metal compounds,[24, 25, 31] but none of the 193 
compounds in this study presented significant inhibitory activity. 194 
To evaluate the ability of the PtII and PtIV compounds under study to intercalate with DNA and 195 
block the action of topoisomerases, topoisomerase I- and topoisomerase-IIa-based gel assays were also 196 
performed.[32] We found that none of the compounds are intercalators or topoisomerase I inhibitors (see 197 
Figure S19, Supporting Information). On the contrary, at 50 mm concentration, topoisomerase-IIa 198 
inhibition was detected for compounds 2a’, 2b’, 3a’, 3b, and 3b’ (see Figure S20, Supporting Information). 199 
In summary, we have presented a new family of luminescent PtII and PtIV (C,N,N’)- 200 
cycloplatinated compounds with high efficacy and selectivity against a broad cancer cell panel. The 201 
studied PtIV compounds presented enhanced efficacy, capacity to be reduced in solution and, importantly, 202 
a complete absence of platinum cross-resistance against metastatic CRC and CRPC multiplatinum-203 
resistant cell models. Indeed, we also proved that the absence of cross-resistance is an intrinsic property 204 
of the platinacycle. Therefore, further modulating the nature of the axial ligands could allow us to 205 
remarkably improve the multitarget action of the compounds, leading to unparalleled levels of efficacy 206 
and to ultimately overcome platinum resistance in the clinics. 207 
  208 
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Legends to figures 275 
 276 
Scheme 1. Synthesis of cyclometallated PtII and PtIV compounds. (i)+ cis-[PtCl2(DMSO)2] and 277 
Na(CH3COO), methanol, reflux, 72 h; (ii)+ KBr, methanol, reflux, 48 h; (iii)+ PhICl2, acetone, r.t., 278 
1 h; (iv)+ Br2, acetone, r.t., 1 h. 279 
 280 
Figure 1. Molecular structure of compound 3a’. Selected bond lengths [a] and angles [8] with estimated 281 
standard deviations: Pt(1)@N(8): 1.984(8); Pt(1)@N(11): 2.253(8); Pt(1)@C(1): 2.019(9); 282 
Pt(1)@Cl(1): 2.320(2); Pt(1)@Cl(2): 2.313(2); Pt(1)@Cl(3): 2.322(2); C(1)-Pt-N(8): 81.6(3); 283 
N(8)-Pt-N(11): 82.2(3); N(11)-Pt-Cl(1): 97.8(2); Cl(1)-Pt-C(1): 98.4(3); Cl(2)-Pt-Cl(1): 90.02(8); 284 
Cl(2)-Pt-N(8): 90.6(2) ; Cl(2)-Pt-N(11): 90.0(2); Cl(2)-Pt-C(1): 87.0(3); Cl(3)-Pt-Cl(1): 90.78(8); 285 
Cl(3)-Pt-N(8): 88.6(2); Cl(3)-Pt-N(11): 93.9(2); Cl(3)-Pt-C(1): 88.8(3). 286 
 287 
Figure 2. Normalized emission spectra of the Pt compounds in dichloromethanesolution at 298 K. lexc 288 
(nm)=385 (2a’), 385 (2b’), 380 (3b’). 289 
 290 
Figure 3. Cell cycle phase distribution at 72 h incubation with cisplatin or 3a’ at their IC50 291 
concentration in (A) SW620-O and (B) SW620-MPR. 292 
 293 
Figure 4. Percentage variations of alive, early apoptotic and late apopto- tic/necrotic cell populations at 294 
72 h incubation with cisplatin or 3a’ at their IC50 concentrations in (A) SW620-O and (B) SW620-MPR 295 
cells. 296 
 297 
Figure 5. Interaction of pBluescript SK+ plasmid DNA (0.3 mg) with increasing concentrations of 298 
compounds under study. A) All compounds were analysed from 10 to 200 mm concentration Lane 1: 299 
DNA only. Lane 5: 10 mm. Lane 6: 25 mm. Lane 7: 50 mm. Lane 8: 100 mm. Lane 9: 200 mm. B) 300 
Compound 2a’ and 2b’ were also analysed at lower concentrations and compared with cisplatin as a 301 
standard reference. Lane 1: 0 mm. Lane 2: 1 mm. Lane 3: 2.5 mm. Lane 4: 5 mm. Lane 5: 10 mm. Lane 302 
6: 25 mm. Lane 7: 50 mm. Lane 8: 100 mm. Lane 9: 200 mm; sc=supercoiled closed circular DNA; 303 
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